NCT06867393View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of HL-003 in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

August 31, 2025

Study Completion Date

September 30, 2025

Conditions
Healthy Subjects
Interventions
DRUG

HL-003 tablet Placeco

100mg、250mg、500mg、1000mg、1500mg，SAD

DRUG

HL-003 tablet

25mg、100mg、250mg、500mg、1000mg、1500mg，SAD

Trial Locations (1)

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Shanghai Kechow Pharma, Inc.

INDUSTRY

NCT06867393 - Safety, Tolerability, and Pharmacokinetics of HL-003 in Healthy Subjects | Biotech Hunter | Biotech Hunter